TY - JOUR
T1 - COVID-19 vaccines
T2 - Knowing the unknown
AU - Lv, Huibin
AU - Wu, Nicholas C.
AU - Mok, Chris K.P.
N1 - Funding Information:
We thank Profs. Roberto Bruzzone and Stanley Perlman for helpful discussions. This work was supported by National Institutes of Health (NIH) K99 AI139445 (N.C.W.), Calmette and Yersin scholarship from the Pasteur International Network Association (H.L.), Guangzhou Medical University High-level University Innovation Team Training Program (Guangzhou Medical University released [2017] No. 159) (C.K.P.M.), National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme (N_HKU737/18) (C.K.P.M.).
Publisher Copyright:
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Vaccine development against SARS-CoV-2 has drawn attention around the globe due to the exploding pandemic. Although COVID-19 is caused by a new coronavirus, SARS-CoV-2, previous research on other coronavirus vaccines, such as FIPV, SARS, and MERS, has provided valuable information for the rapid development of COVID-19 vaccine. However, important knowledge gaps remain — some are specific to SARS-CoV-2, others are fundamental to immunology and vaccinology. Here, we discuss areas that need to be addressed for COVID-19 vaccine development, and what can be learned from examples of vaccine development in the past. Since the beginning of the outbreak, the research progress on COVID-19 has been remarkable. We are therefore optimistic about the rapid development of COVID-19 vaccine.
AB - Vaccine development against SARS-CoV-2 has drawn attention around the globe due to the exploding pandemic. Although COVID-19 is caused by a new coronavirus, SARS-CoV-2, previous research on other coronavirus vaccines, such as FIPV, SARS, and MERS, has provided valuable information for the rapid development of COVID-19 vaccine. However, important knowledge gaps remain — some are specific to SARS-CoV-2, others are fundamental to immunology and vaccinology. Here, we discuss areas that need to be addressed for COVID-19 vaccine development, and what can be learned from examples of vaccine development in the past. Since the beginning of the outbreak, the research progress on COVID-19 has been remarkable. We are therefore optimistic about the rapid development of COVID-19 vaccine.
KW - COVID-19
KW - SARS-CoV-2
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85086240400&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086240400&partnerID=8YFLogxK
U2 - 10.1002/eji.202048663
DO - 10.1002/eji.202048663
M3 - Comment/debate
C2 - 32437587
AN - SCOPUS:85086240400
SN - 0014-2980
VL - 50
SP - 939
EP - 943
JO - European Journal of Immunology
JF - European Journal of Immunology
IS - 7
ER -